SCHEMBL20908829

SCHEMBL20908829

CNC(S)N1CCC[C@H]1C1=CCN(C)CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20908877 0.84 QDPR (0.31) —
SCHEMBL18923573 0.82 — —
SCHEMBL20908828 0.81 — —
SCHEMBL19273202 0.78 QDPR (0.33) —
SCHEMBL18923571 0.77 QDPR (0.31) —
SCHEMBL18923605 0.77 QDPR (0.32) —
SCHEMBL22541519 0.76 QDPR (0.30) —
SCHEMBL20319917 0.76 QDPR (0.31) —
SCHEMBL19273205 0.76 QDPR (0.31) —
SCHEMBL20706018 0.76 QDPR (0.33) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10385039-B2 Bicyclic aza compounds as muscarnic M1 receptor and/or M4 receptor antagonists HEPTARES THERAPEUTICS LIMITED (GB) 2019-08-20 — — US disclosed
US-20190112294-A1 BICYCLIC AZA COMPOUNDS AS MUSCARNIC M1 RECEPTOR AND/OR M4 RECEPTOR ANTAGONISTS NXERA PHARMA UK LIMITED (GB) 2019-04-18 — — US disclosed
Send feedback